SciClone Pharmaceuticals (Holdings) (HKSE:06600) Total Inventories : HK$337 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Total Inventories?

SciClone Pharmaceuticals (Holdings)'s total inventories for the quarter that ended in Dec. 2023 was HK$337 Mil. SciClone Pharmaceuticals (Holdings)'s average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was HK$232 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. SciClone Pharmaceuticals (Holdings)'s Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$4.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. SciClone Pharmaceuticals (Holdings)'s Days Inventory for the six months ended in Dec. 2023 was 98.96.

Inventory Turnover measures how fast the company turns over its inventory within a year. SciClone Pharmaceuticals (Holdings)'s Inventory Turnover for the quarter that ended in Dec. 2023 was 1.84.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. SciClone Pharmaceuticals (Holdings)'s Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.14.

SciClone Pharmaceuticals (Holdings) Total Inventories Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Total Inventories Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

156.01

203.40

213.87

156.97

337.20

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial						213.87	175.68	156.97	126.35	337.20

SciClone Pharmaceuticals (Holdings) Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

SciClone Pharmaceuticals (Holdings)'s Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2431.788	+	0.75 * 949.35	+	0.5 * 337.196	-	804.128
-	0	-	0)	/	626.973
=	4.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

SciClone Pharmaceuticals (Holdings)'s Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	231.774	/	427.446	*	365 / 2
	=	98.96

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

SciClone Pharmaceuticals (Holdings)'s Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	427.446	/	231.774
	=	1.84

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

SciClone Pharmaceuticals (Holdings)'s Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	231.774	/	1697.854
	=	0.14

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

SciClone Pharmaceuticals (Holdings) Total Inventories Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Total Inventories

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines